Racotumomab for treating lung cancer and pediatric refractory malignancies

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

(2015) G. Giaccone et al.   EUROPEAN JOURNAL OF CANCER

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

(2015) Luis Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies

(2015) Walter Cacciavillano et al.   PEDIATRIC BLOOD & CANCER

SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings

(2015) Nehal S. Parikh et al.   PEDIATRIC BLOOD & CANCER

Immunoreactivity of the 14F7 Mab raised againstN-Glycolyl GM3 Ganglioside in retinoblastoma tumours

(2014) Ana Vanesa Torbidoni et al.   ACTA OPHTHALMOLOGICA

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

(2014) Brian H. Kushner et al.   CLINICAL CANCER RESEARCH

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients

(2014) S. Alfonso et al.   CLINICAL CANCER RESEARCH

Immunotherapy for non-small-cell lung cancer

(2014) Anish Thomas et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

(2014) Christian Rolfo et al.   Expert Review of Anticancer Therapy

Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer

(2014) Ana María Hernández et al.   Expert Review of Vaccines

Therapeutic antibodies to intracellular targets in cancer therapy

(2013) Nicholas Veomett et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

(2013) Johan Vansteenkiste et al.   JOURNAL OF CLINICAL ONCOLOGY

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody

(2012) Nobuyoshi Hayashi et al.   CANCER SCIENCE

Promising Therapeutic Targets in Neuroblastoma

(2012) K. K. Matthay et al.   CLINICAL CANCER RESEARCH

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

(2012) Julie R. Park et al.   PEDIATRIC BLOOD & CANCER

Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer

(2012) Valeria I. Segatori et al.   Frontiers in Oncology

Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements

(2012) Maha Z. Ladjemi   Frontiers in Oncology

Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer

(2011) Alejandra M. Scursoni et al.   Clinical & Developmental Immunology

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines

(2010) Luis E. Fernandez et al.   Clinical & Developmental Immunology

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

(2009) Hester van Cruijsen et al.   BMC CANCER

Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model

(2009) D. Fuentes et al.   BREAST CANCER RESEARCH AND TREATMENT

MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy

(2009) Preeta Tyagi et al.   Clinical Lung Cancer

Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy

(2009) Mayrel Labrada et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility

(2009) Sen-itiroh Hakomori   FEBS LETTERS

Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1)

(2009) Marina Larrain et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Detection and Characterization of N-Glycolyated Gangliosides in Wilms Tumor by Immunohistochemistry

(2009) Alejandra M. Scursoni et al.   PEDIATRIC AND DEVELOPMENTAL PATHOLOGY

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

(2008) Y. Diaz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function

(2008) J. de Leon et al.   INTERNATIONAL IMMUNOLOGY

Dissecting lipid raft facilitated cell signaling pathways in cancer

(2007) Samir Kumar Patra   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER